Document ID: chunk:federal_register_of_legislation:F2024C01228:front:0:p10
Version: federal_register_of_legislation:F2024C01228
Segment Type: other
Provision Reference: 
Character Range: 23378–26110

of the vaccine under subparagraph (i) – 2 primary doses with at least 8 weeks between doses and a booster at least 8 months after the second dose was provided;
         (b) a person who is an Aboriginal and Torres Strait Islander; and

            (i) who has one of the following medical conditions known to increase the risk of Invasive Meningococcal Disease (IMD):

                    (A) defects in, or deficiency of, complement components, including factor H, factor D or properdin deficiency; or

                    (B) current or future treatment with eculizumab (a monoclonal antibody directed against complement component C5); or

                    (C) functional or anatomical asplenia, including sickle cell disease or other haemoglobinopathies, and congenital or acquired asplenia; or

                    (D) HIV, regardless of disease stage or CD4+ cell count; or

                    (E) haematopoietic stem cell transplant;

            (ii) may be provided the following number of doses and booster doses:
                    (A) if aged at least 2 months of age at start of vaccine course – 3 primary doses with at least 8 weeks between doses and a booster aged at least 12 months;
                    (B) if aged under 2 years of age at start of vaccine course  – 3 primary doses with at least 8 weeks between doses and a booster at least 6 months after the third dose was provided;
         (c) The following number of doses and booster doses may be provided to a person who has congenital or acquired asplenia (e.g. splenectomy) or hyposplenia, a person who has complement deficiency or a person undergoing eculizumab treatment:

            (i) if aged 6 weeks to 5 months of age at start of vaccine course – 3 primary doses with at least 8 weeks between doses and a booster dose aged at least 12 months;
            (ii) if aged between 6 and 11 months at start of vaccine course – 2 primary doses with at least 8 weeks between doses and a booster dose aged at least 12 months;
            (iii) if aged at least 12 months of age at start of vaccine course – 2 primary doses with at least 8 weeks between doses.
 (14) For item 218A of Schedule 1, three doses of a designated vaccine mentioned in that item may be provided to a person who:
 (a) is at least 12 years of age but less than 26 years of age; and
 (b) has impaired immunity;
  with the three doses provided 6 to 12 months apart.
 (15) For item 217A of Schedule 1, a designated vaccine mentioned in that item may be provided to a person who is at least 18 years of age and is considered at increased risk of herpes zoster in any of the following circumstances, noting that more than one circumstance may be applicable:
 (a) has an underlying